BNP Paribas Financial Markets Boosts Stake in uniQure (NASDAQ:QURE)

BNP Paribas Financial Markets lifted its holdings in uniQure (NASDAQ:QURE) by 9.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 468,357 shares of the biotechnology company’s stock after buying an additional 41,166 shares during the quarter. BNP Paribas Financial Markets’ holdings in uniQure were worth $8,271,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Boxer Capital Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at approximately $13,245,000. Schonfeld Strategic Advisors LLC acquired a new position in uniQure during the fourth quarter worth $9,473,000. Northern Trust Corp raised its holdings in uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after purchasing an additional 1,923 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 1,371 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in uniQure during the fourth quarter worth $681,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at uniQure

In related news, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This trade represents a 1.14% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by insiders.

uniQure Stock Performance

NASDAQ QURE opened at $12.78 on Monday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The stock has a market cap of $700.04 million, a price-to-earnings ratio of -2.58 and a beta of 0.10. The business has a fifty day moving average of $12.22 and a 200-day moving average of $12.13. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on QURE. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. StockNews.com raised uniQure to a “sell” rating in a report on Tuesday, March 11th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price objective on shares of uniQure in a report on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.